Cihan Ay and Colleagues on Thromboembolism and Bleeding in Multiple Myeloma
RPTH Journal shared on LinkedIn:
”In newly diagnosed multiple myeloma patients on immunomodulatory drugs, VTE and bleeding risks remain high.
Direct oral anticoagulants showed a trend toward lower VTE vs aspirin/no prophylaxis, but bleeding rates were similar across all strategies.
Check out the full article for more details.”
Read the full article in RPTH.
Article: Thromboembolism and bleeding in newly diagnosed multiple myeloma: rates, risk profile, and patterns of thromboprophylaxis
Authors: Lea Vospernik, Hermine Agis, Cihan Ay, Lina Rüsing, Heinz Gisslinger, Christina Brunbauer, Clara Sophie Michel, Ingrid Simonitsch-Klupp, Alexandra Kaider, Maria-Theresa Krauth, Julia Riedl
Stay updated on all scientific advances in the field of clotting disorders with Hemostasis Today.
-
Jan 7, 2026, 13:57Joshua Muia: Delighted to Welcome X. Long Zheng for a Versiti Seminar on TTP
-
Jan 7, 2026, 13:40Marilena Vrana Invites You to IPPC2026
-
Jan 7, 2026, 13:32Carlos Villa Joins Versiti Blood Research Institute
-
Jan 7, 2026, 13:21Bartosz Hudzik: New Evidence on “Aspirin Failure” After Ischemic Stroke
-
Jan 7, 2026, 08:50Fahad Khaliq on When is Ticagrelor Preferred Over Other Antiplatelets
-
Jan 7, 2026, 06:41Zain Khalpey on AI Driven Risk Prediction for Optimization of Anticoagulation in LVAD
-
Jan 7, 2026, 05:47Michael Makris: The Wakley Prize Essay Published in Today’s Lancet is an Excellent Read
-
Jan 7, 2026, 05:36Pierre F Sabouret Shares A Study on the Risk of Cardiovascular Death in SIDs
-
Jan 7, 2026, 05:15Glaivy Batsuli Reflects on ASH25